Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tusamitamab ravtansine
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Tusamitamab ravtansine is an antibody-drug conjugate (ADC) designed to target tumor cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). It consists of a humanized monoclonal antibody selective for the extracellular domain of CEACAM5, linked via a cleavable disulfide linker to DM4, a potent cytotoxic maytansinoid payload. Upon intravenous administration, the antibody binds to CEACAM5 on tumor cells and is internalized; intracellular cleavage releases DM4, which inhibits microtubule assembly leading to cell-cycle arrest and apoptosis. The drug was primarily developed for advanced solid tumors with high CEACAM5 expression, especially non-squamous non-small cell lung cancer (NSCLC). Sanofi discontinued its global clinical development in December 2023 after failing to meet primary endpoints in Phase 3 trials for NSCLC[1][2][3][4][6].
- Other names
- maytansin-loaded anti-ceacam5 mab
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on tusamitamab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tusamitamab ravtansine.